IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

The article says oncology experts and company management will discuss the Phase 3 OVATION 3 study, emphasizing supporting science, clinical progress, and upcoming milestones. No efficacy/safety results or milestone dates are quantified here, so the news reads as a promotional/communication update rather than a new catalyst. Overall, it modestly improves sentiment around continued development progress.